With the increasing severity of bacterial antibiotic resistance， finding new ways to overcome this global challenge has become an urgent task. Chinese medicine， with abundant resources， offers potential for discovering diverse bioactive ingredients to enhance antibiotic efficacy and alleviate the crisis of bacterial antibiotic resistance. This review summarizes bacterial resistance mechanisms， prevention strategies， and the roles and mechanisms of Chinese medicine and its active ingredients in enhancing the efficacy of existing antibiotics. Two major resistance mechanisms—bacterial obstruction of antibiotic uptake and weakening of intracellular antibiotic activity—are introduced， with corresponding prevention and control strategies outlined. Based on the regulatory effects of active ingredients from Chinese medicine on bacteria， their mechanisms for enhancing antibiotic efficacy are categorized into two types， including improving the bacterial uptake of antibiotics and reducing the bacterial resistance to antibiotics. The former mainly enhances extracellular antibiotic uptake by regulating membrane permeability， biofilm formation， and metabolic pathways. The latter weakens intracellular antibiotic resistance by inhibiting efflux pumps and bacterial resistance targets. Furthermore， compound formulas of Chinese medicine， characterized by multi-component， multi-target， and multi-pathway interventions， exert similar antimicrobial effects and mechanisms with active ingredients， offering rich resources for developing antibiotic-enhancing applications. Finally， the review highlights the challenges such as insufficient structural research on active ingredients and potential druggability issues in their application for antibiotic enhancement. This will provide insights for advancing the research on Chinese active ingredients in antibiotic therapy and offers novel strategies to combat bacterial antibiotic resistance.

With the increasing severity of bacterial antibiotic resistance， finding new ways to overcome this global challenge has become an urgent task. Chinese medicine， with abundant resources， offers potential for discovering diverse bioactive ingredients to enhance antibiotic efficacy and alleviate the crisis of bacterial antibiotic resistance. This review summarizes bacterial resistance mechanisms， prevention strategies， and the roles and mechanisms of Chinese medicine and its active ingredients in enhancing the efficacy of existing antibiotics. Two major resistance mechanisms—bacterial obstruction of antibiotic uptake and weakening of intracellular antibiotic activity—are introduced， with corresponding prevention and control strategies outlined. Based on the regulatory effects of active ingredients from Chinese medicine on bacteria， their mechanisms for enhancing antibiotic efficacy are categorized into two types， including improving the bacterial uptake of antibiotics and reducing the bacterial resistance to antibiotics. The former mainly enhances extracellular antibiotic uptake by regulating membrane permeability， biofilm formation， and metabolic pathways. The latter weakens intracellular antibiotic resistance by inhibiting efflux pumps and bacterial resistance targets. Furthermore， compound formulas of Chinese medicine， characterized by multi-component， multi-target， and multi-pathway interventions， exert similar antimicrobial effects and mechanisms with active ingredients， offering rich resources for developing antibiotic-enhancing applications. Finally， the review highlights the challenges such as insufficient structural research on active ingredients and potential druggability issues in their application for antibiotic enhancement. This will provide insights for advancing the research on Chinese active ingredients in antibiotic therapy and offers novel strategies to combat bacterial antibiotic resistance.

Objective To investigate the efficacy of nimodipine combined with donepezil in the treatment of CSVD patients with mild cognitive impairment.Methods A total of 130 CSVD pa-tients admitted to our department from October 2020 to October 2023 were recruited and ran-domly divided into monotherapy group(nimodipine,65 cases)and combined group(nimodipine plus donepezil,65 cases).The clinical efficacy after 3 months of treatment was recorded.The blood-brain barrier function and brain function indicators[serum neuron-specific enolase(NSE),vascular endothelial growth factor(VEGF),central nervous system specific protein(S100β)]were compared between the two groups.Results The clinical efficacy was significantly higher in the combined group than the monotherapy group(92.3％vs 78.5％,P＜0.05).The cerebrospinal fluid albumin and blood-brain barrier index were obviously increased in the two groups after treatment(P＜0.05),and the two indicators were notably lower in the combined group than the monothera-py group(P＜0.01).After treatment,the level of VEGF was remarkably elevated while those of NSE and S100β were marvelously reduced in the two groups when compared with the levels be-fore treatment(P＜0.05).The combined group obtained significantly higher VEGF level but low-er NSE and S100β levels than the monotherapy group after treatment(P＜0.01).Conclusion For CSVD patients with mild cognitive impairment,the combination of nimodipine and donepezil can effectively improve the cognitive impairment,and promote the brain function recovery.

Microtubulin disease，which is rare in prenatal settings，is characterized by severe brain developmental abnormalities due to mutations in the microtuberin gene.In this article，a patient diagnosed with TUBB3-related microtubule proteinopathy during prenatal testing was reported，serving as a reference for prenatal physicians. A 33-year-old pregnant woman，who was 23 +5 weeks pregnant，visited to Peking University First Hospital Ningxia Women and Children's Hospital. During a prenatal ultrasound examination，it was discovered that the fetal brain midline was curved，the septum pellucida was twisted，the left lateral fissure had an oblique platform shape，the left lateral ventricle was enlarged，and there were left thoracic cystadenoma and right ventricular hyperechoic plaques. Whole exome sequencing was performed and revealed a mutation in the TUBB3 gene. The pregnancy was terminated at 26 +6 weeks of gestation. Prenatal ultrasound can detect some signs of microtubule protein disease，and genetic testing is recommended for prenatal diagnosis to comprehensively assess the prognosis of the fetus.

OBJECTIVE: To explore the genetic etiology of four fetuses with Uniparental disomy (UPD), and analyze their causes. METHODS: Four fetuses undergoing prenatal diagnosis at Wenzhou Central Hospital between November 2021 and July 2024 were selected as the study subjects. Genetic testing and diagnosis were carried out through G-banded chromosomal karyotyping, single nucleotide polymorphism array (SNP-array) and methylation multiplex ligation-dependent probe amplification (MS-MLPA). This study was approved by the Medical Ethics Committee of the Hospital (Ethics No.: L2024-11-028). RESULTS: The four cases of pathogenic UPD had involved chromosomes 2, 11, 15 and 16, respectively, of which 2 cases were accompanied by fetal ultrasound abnormalities, One fetus was shown a high risk by serological screening, while another showed a high risk by non-invasive DNA testing. The karyotype of fetus 1 was 45,X?,rob(13;15)(q10;q10), and its parents had both carried a Robertsonian translocation involving chromosomes 13 and 15, whilst the karyotypes of other three fetuses were all normal. Pedigree analysis indicated that the UPDs in three cases were paternally derived, and the remaining one was unknown. The causes of the four cases included imprinting syndrome in two cases, autosomal recessive disorder in one case, and cryptic mosaic trisomy in one case. CONCLUSION The clinical phenotypes of UPD are diverse, and the mechanisms are complex. Combined chromosomal karyotyping, SNP-array, MS-MLPA and other technologies are required to make a clear diagnosis for prenatal genetic counseling and postnatal management.
Humans ; Uniparental Disomy/diagnosis* ; Female ; Pregnancy ; Prenatal Diagnosis/methods* ; Polymorphism, Single Nucleotide/genetics* ; Karyotyping ; Adult ; Genetic Testing ; Male ; Fetus

Objective:To comparatively evaluate the efficacy of anti-tumor necrosis factor (TNF)-α and anti-interleukin (IL)-12/23 biologics as the first-line treatment in Crohn′s disease (CD).Methods:From January 1, 2016 to December 31, 2024, at the Department of Gastroenterology of the First Affiliated Hospital of Soochow University, the clinical data of patients with CD treated with anti-TNF-α (infliximab or adalimumab) or anti-IL-12/23 biologics (ustekinumab) as first-line treatment were retrospectively collected. All the patients were followed up for 1 year since the initiation of first-line biologic treatment, with the follow-up concluding on December 31, 2024. The primary outcomes were the clinical efficacy (including clinical response rate and clinical remission rate) of anti-TNF-α or anti-IL-12/23 treatment at week 24 and week 48, and the endoscopic efficacy(including endoscopic response rate and endoscopic remission rate) at week 48. The clinical efficacy was assessed based on Crohn′s disease activity index(CDAI). The clinical response was defined as a reduction in CDAI by ≥ 70 from baseline (week 0), and clinical remission was defined as CDAI < 150. The endoscopic efficacy was assessed based on simple endoscopic score for Crohn′s disease (SES-CD), the endoscopic response was defined as a reduction in SES-CD by ≥50% from baseline (week 0), and endoscopic remission was defined as SES-CD ≤2. Chi-square test or Fisher′s exact test was used for statistical analysis.Results:A total of 215 CD patients were enrolled, including 160 males and 55 females, with the age of (31.88±11.55) years old. Among them, 179 patients completed the clinical efficacy evaluation, 110 cases were treated with anti-TNF-α, 69 cases were treated with anti-IL-12/23. The clinical response rates of patients treated with anti-TNF-α and anti-IL-12/23 at week 24 were 95.5%(105/110) and 95.7%(66/69), respectively, and the clinical remission rates at week 24 were 86.4%(95/110) and 85.5%(59/69), respectively; the clinical response rates at week 48 were 95.5%(105/110) and 97.1%(67/69), respectively, and the clinical remission rates at week 48 were 89.1%(98/110) and 88.4%(61/69), respectively; and the differences were not statistically significant(Fisher′s exact test, χ2=0.03, Fisher′s exact test, χ2=0.02; P=1.000, 0.708, 0.872, and 0.887). A total of 76 patients completed endoscopic efficacy evaluation, among which 55 cases were treated with anti-TNF-α, and 21 cases were treated with anti-IL-12/23. The endoscopic response rates of patients treated with anti-TNF-α and anti-IL-12/23 were 74.5%(41/55) and 66.7%(14/21), respectively, and the endoscopic remission rates at week 48 were 49.1%(27/55) and 28.6%(6/21), respectively; and the differences were not statistically significant( χ2=0.47 and 2.60, P=0.492 and 0.107). Conclusion:Both anti-TNF-α and anti-IL-12/23 are effective as first-line biological therapies for CD, and there are no significant differences in both clinical and endoscopic efficacy between these 2 biologics.

Objective:To compare the role of double-balloon enteroscopy (DBE) and dual-energy CT enterography (DCTE) in evaluating the clinical characteristics of Crohn′s disease (CD).Methods:From July 1, 2016 to November 1, 2023, 72 patients with CD who underwent both DBE and DCTE (with an interval of less than 3 months) in the First Affiliated Hospital of Soochow University were enrolled in this retropective study. Among them, 4 patients underwent both DBE and DCTE twice (a total of 76 cases). The data of DBE and DCTE in the diagnosis of 76 CD cases were analyzed, including the diagnostic rate of CD, the consistency of the 2 methods in detecting the lesion location (ileocecal, colonic, ileocolonic, and upper gastrointestinal tract involvement), and the detection rates of stenosis, ulcer and the location, long ulcer (long-diameter≥2 cm), and fistula. Kappa test was performed for the consistency analysis, and Chi-square test was used for statistical analysis.Results:The diagnostic rate of CD by DBE was higher than that by DCTE (80.3% (61/76) vs. 65.8% (50/76)), and the diagnostic rate of combination of the 2 methods (89.5% (68/76)) was higher than that by DCTE alone, and the differences were statistically significant ( χ2=4.04 and 12.28, P=0.044 and <0.001). The result of Kappa consistency test showed that the consistency of CD lesion location detected by DBE and DCTE was poor (Kappa value=0.29, t=3.17, P=0.002). The detection rate of stenosis by DBE was higher than that by DCTE (46.1% (35/76) vs. 13.2% (10/76)), the detection rate of stenosis by combination of the 2 methods (52.6% (40/76)) was higher than that by DCTE alone, and the differences were statistically significant ( χ2=19.73 and 26.82, both P<0.001). There were no statistically significant differences in the detection rates of fistula among DBE, DCTE, and the combination of the 2 methods (3.9%(3/76), 2.6% (2/76), 5.3% (4/76); all P>0.05). The detection rate of ulcer by DBE was higher than that by DCTE(73.7% (56/76) vs. 7.9% (6/76)), the detection rate of ulcer by combination of the 2 methods (76.3%(58/56)) was higher than that by DCTE alone, and the differences were statistically significant ( χ2=68.10 and 72.98, both P<0.001). The detection rates of long ulcer and non-terminal ileum ulcer by DBE were both 17.9% (10/56). All the 6 cases with ulcer detected by DCTE were located in the terminal ileum, and no long ulcers were observed. Conclusions:In the diagnosis of CD, as well as in the detection of stenosis and ulcer, DBE and the combination of DBE and DCTE have more advantages over DCTE alone. The consistency between DBE and DCTE in identifying the location of lesion is poor. DBE has advantages in detecting long ulcer and non-terminal ileum ulcer.

The incidence of digestive system diseases is high. So digestive system pathology is widely concerned. In the past 10 years, Chinese pathologists insist on hard work and have made significant progress. This article reviews the research and practice progress in digestive system tumors and non-tumors in the past 10 years, including the establishment of diagnostic criteria for gastrointestinal tract, hepatobiliary and pancreatic diseases, the establishment and classification of new diseases with special morphology, the classification and standard update of gastrointestinal and pancreatic neuroendocrine tumors, the progress of molecular pathology, and non-tumor lesions of the digestive system. The future development trend of digestive system pathology is also prospected.

The incidence of digestive system diseases is high. So digestive system pathology is widely concerned. In the past 10 years, Chinese pathologists insist on hard work and have made significant progress. This article reviews the research and practice progress in digestive system tumors and non-tumors in the past 10 years, including the establishment of diagnostic criteria for gastrointestinal tract, hepatobiliary and pancreatic diseases, the establishment and classification of new diseases with special morphology, the classification and standard update of gastrointestinal and pancreatic neuroendocrine tumors, the progress of molecular pathology, and non-tumor lesions of the digestive system. The future development trend of digestive system pathology is also prospected.